Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital

National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund

Learn More

Oncology 2020: Key Challenges That Will Impact Health Plans

April 2020

Download the white paper

Data Driven Utilization Management, Purpose Built for Oncology

Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology

Learn More

A Patient-First Approach to Cancer Care

Learn more about Oncology Analytics’ mission to ensure that all patients receive the best possible evidence-based treatment, tailored to their unique personal needs

Watch the Video

Oncology Analytics named to CB Insights’ Digital Health 150

The most promising 150 private digital health startups working to transform the healthcare industry with new models of primary care to emerging tech solutions for providers

Learn More

Today’s cancer treatments are varied, complicated and costly. Oncology treatment costs are soaring and forecast to hit $105 billion in the US by 2023, driven primarily by availability and favorable reimbursement of new medicines.

Oncology Analytics provides the critical missing link for health plans by helping to manage the total cost of cancer care. By providing access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, health plans are able to provide their members with the ability to achieve the best possible outcomes.

Improved outcomes are possible when treatment options are tailored to the unique needs of the patient. Ensuring that patients receive the optimal treatment that balances efficacy, toxicity and affordability lie at the heart of Oncology Analytics’ mission.

Join the conversation

Subscribe to our newsletter

Solutions

e-Prior Authorization

Data-driven through advanced analytics, we help health plans determine the right anti-cancer therapies, then tailor our oncology e-Prior Authorization (ePA) platform to allow treating oncologists to initiate and manage their ePA requests securely through our cloud-based software, which eliminates manual faxing and phone calls, while improving operational efficiency
Read More

Oncology Insights™

Next-generation, real-world data analytic software solution, combined with oncology-focused clinical expertise, equips health plans with superior insight into their provider network, cancer drug trend and spend, cancer treatment decision-making capabilities, and powerful comparative benchmarks
Read More

Pharmacy Consulting

A highly focused group of experienced and board-certified oncology pharmacy professionals, who partner with health plans to keep them up to date on the rapidly changing cancer therapy landscape to improve member care and ensure proper financial impact for the health plan
Read More

News

Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital

National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund Atlanta, GA, May 26, 2020 — Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health...

Oncology Analytics Appoints Dr. Andrew Norden As Chief Medical Officer

Former Dana-Farber Associate Chief Medical Officer to Lead Company’s Clinical Team and Innovation Strategy

« Older Entries

Articles & Press

CheckMate 9LA: Nivolumab and Ipilimumab plus 2 Cycles of Platinum-Doublet Chemotherapy vs. 4 Cycles of Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

The following article, written by Adam Peele, PharmD, MHA, BCPS, BCOP, Director of Pharmacy Operations at Oncology Analytics, is the second of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held May 29-31, 2020.

KEYNOTE-355: Phase III study of pembrolizumab plus chemotherapy for previously untreated metastatic triple-negative breast cancer

The following article, written by Laura R. Bobolts, Senior Vice President of Pharmacy at Oncology Analytics, is the first of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held in...

« Older Entries